Investopedia: Drugs Don't Cure All That Ails J&J

Not liking Johnson & Johnson (NYSE:JNJ) can sometimes feel tantamount to not liking apple pie or capitalism itself. True, JNJ is among the bluest of blue chips and a company with incredible staying power. And yet, the idea of investing in individual stocks is to outperform the broader markets, and JNJ is not necessarily the best option for that goal. (To help you pick stocks, check out How To Pick A Stock.)

Mediocre Q2 Results  
Johnson & Johnson did not report a bad second quarter result, but nor was it an exceptionally strong quarter. Revenue rose about 8% as reported, but organic growth was a much more modest 2%. Growth was led by the pharmaceutical group where sales were up more than 5% on an organic basis. Devices were less impressive at just over 1% growth, and the consumer business was down almost 2% on an organic basis. 


Read more:
http://stocks.investopedia.com/stock-analysis/2011/Drugs-Dont-Cure-All-That-Ails-JJ-JNJ-PFE-ABT-BSX-STJ-COV-MDT0720.aspx